Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA1c in T2DM,Annals of Internal Medicine

当前位置： X-MOL 学术 › Ann. Intern. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA1c in T2DM
Annals of Internal Medicine ( IF 19.6 ) Pub Date : 2021-09-07 , DOI: 10.7326/acpj202109210-106
Miranda K Boggild ₁ , Angela M Cheung ₁

Affiliation

Source Citation

Giugliano D, Longo M, Caruso P, et al. Feasibility of simplification from a basal-bolus insulin regimen to a fixed-ratio formulation of basal insulin plus a GLP-1RA or to basal insulin plus an SGLT2 inhibitor: BEYOND, a randomized, pragmatic trial. Diabetes Care. 2021;44:1353-60. https://pubmed.ncbi.nlm.nih.gov/33883195

Clinical Impact Ratings

GIM/FP/GP: 6 out of 7

Endocrinology: 6 out of 7

中文翻译：

基础胰岛素加 GLP-1 RA 或 SGLT2 抑制剂对于 T2DM 中的 HbA1c 不劣于基础推注胰岛素强化

来源引用

Giugliano D、Longo M、Caruso P 等。从基础推注胰岛素方案简化为基础胰岛素加 GLP-1RA 或基础胰岛素加 SGLT2 抑制剂的固定比例配方的可行性：BEYOND，一项随机、务实的试验。糖尿病护理。2021；44：1353-60。https://pubmed.ncbi.nlm.nih.gov/33883195

临床影响评级

GIM/FP/GP： 7 个中的 6 个

内分泌科： 7 个中的 6 个

更新日期：2021-09-07

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11